Mobile Health Case Management System for Reducing Pediatric Treatment Abandonment
Burkitt Lymphoma, Retinoblastoma, Diffuse Large B-cell Lymphoma
About this trial
This is an interventional health services research trial for Burkitt Lymphoma focused on measuring Digital Health, Pediatric Cancer, Low and middle-income country, Tanzania, Healthcare provider decision support, Protocol-driven treatment, Burkitt lymphoma, Retinoblastoma, Treatment abandonment, Client health records, Diffuse large B-cell lymphoma
Eligibility Criteria
There are two categories of participants: Patients with Burkitt Lymphoma, Diffuse large B-cell lymphoma or retinoblastoma; and health providers at BMC who participate in testing and/or use of mNavigator. Eligibility criteria are as follows:
A) For patients:
*All patients will be registered in the pre-diagnosis cohort but, for the purposes of this study, primary and secondary outcomes will only be tracked for patients with BL, DLBCL or RB once the diagnosis is made.
Inclusion Criteria:
- Inclusion criteria are pediatric oncology patients diagnosed with Burkitt Lymphoma, Diffuse large B-cell lymphoma or Retinoblastoma under the age of 18
Exclusion criteria:
- Patients older than 18 years at registration
- Patients with diagnoses other than Burkitt lymphoma, Diffuse large B-cell lymphoma or retinoblastoma.
B) For providers:
Inclusion Criteria:
- Must be health provider or staff working at BMC who provides care for cancer patients.
- Must be 18 years of age or older.
Exclusion:
- Persons younger than 18 years of age.
Sites / Locations
- Bugando Medical Centre
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
mNavigator
Historical controls
Allied health providers will use mNavigator to guide diagnosis and treatment for pediatric cancer patients at Bugando Medical Centre (BMC).
BL (DLBCL)/Rb retrospective patients (treated between 2015-2019) when standardized treatment protocols for BL (DLBCL) and Rb were introduced at BMC.